Furthermore, treating EGFR mutant NSCLC cells with a pan‐PI3K inhibitor BKM120 led to a significant drop of the proliferation ability of PAICS knockdown cells (Figure S4C), suggesting the activated PI3K‐AKT signaling could compromise the effect of PAICS knockdown. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.